Microlearning Interactive Virtual Presentations

Share

Program Content

Activities

  • 1L: High-Risk Patient
    Cases in CLL: High-Risk Patient Requiring First-line Therapy
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2020

    Expires: September 27, 2021

  • 1L: Fit Patient
    Cases in CLL: Fit, Younger Patient Requiring First-line Therapy
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2020

    Expires: September 27, 2021

  • 2L: Post-CIT Therapy
    Cases in CLL: Second-Line Therapy Following Chemoimmunotherapy
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2020

    Expires: September 27, 2021

  • 2L+: Ibrutinib Intolerance
    Cases in CLL: Patient Progressing on BR With Subsequent Ibrutinib Intolerance
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 01, 2020

    Expires: September 30, 2021

  • 1L: Older Patient
    Cases in CLL: Options for an Older Patient Requiring First-line Therapy
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 12, 2020

    Expires: October 11, 2021

  • 3L: Post BTKi/VenR
    Cases in CLL: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 14, 2020

    Expires: October 13, 2021

Faculty

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Matthew S. Davids, MD, MMSc

Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner